Author:
Fakih Marwan,Raghav Kanwal Pratap Singh,Chang David Z.,Larson Tim,Cohn Allen L.,Huyck Timothy K.,Cosgrove David,Fiorillo Joseph A.,Tam Rachel,D'Adamo David,Sharma Neelesh,Brennan Barbara J.,Wang Ying A.,Coppieters Sabine,Zebger-Gong Hong,Weispfenning Anke,Seidel Henrik,Ploeger Bart A.,Mueller Udo,Oliveira Carolina Soares Viana de,Paulson Andrew Scott
Funder
Bayer Fund
Bristol-Myers Squibb Co
Bayer HealthCare Pharmaceuticals Inc
Reference39 articles.
1. Regorafenib (Stivarga). European Medicines Agency: summary of product characteristics;Bayer,2022
2. Regorafenib (Stivarga) U.S Food and Drug Administration prescribing information,2020
3. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Cervantes;Ann Oncol,2023
4. Nivolumab (Opdivo). U.S. Food and Drug Administration prescribing information,2021
5. Pembrolizumab (Keytruda) U.S Food and Drug Administration prescribing information,2020
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献